XY Capital Ltd acquired a new position in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 46,676 shares of the company's stock, valued at approximately $673,000. HUTCHMED comprises about 0.3% of XY Capital Ltd's holdings, making the stock its 22nd largest position.
A number of other institutional investors and hedge funds have also made changes to their positions in HCM. Public Employees Retirement System of Ohio acquired a new stake in shares of HUTCHMED during the 3rd quarter worth $35,000. Blue Trust Inc. increased its holdings in HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock valued at $69,000 after purchasing an additional 3,057 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in HUTCHMED by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company's stock valued at $117,000 after purchasing an additional 2,321 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in HUTCHMED in the 2nd quarter valued at $213,000. Finally, Crossmark Global Holdings Inc. increased its holdings in HUTCHMED by 10.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock valued at $268,000 after purchasing an additional 1,799 shares in the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.
HUTCHMED Stock Up 1.0 %
NASDAQ HCM traded up $0.13 during trading hours on Thursday, hitting $13.22. The company had a trading volume of 110,094 shares, compared to its average volume of 85,917. HUTCHMED has a fifty-two week low of $12.84 and a fifty-two week high of $21.92. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm's 50 day moving average is $14.54 and its 200 day moving average is $17.07.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
Read Our Latest Analysis on HUTCHMED
HUTCHMED Company Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
